Meeting
2016 Genitourinary Cancers Symposium
Angiogenic markers during bevacizumab-based treatment in metastatic renal cell carcinoma (RCC).
Authors
Tanya B. Dorff
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA
Tanya B. Dorff , Jeff Longmate , Susan G. Groshen , Walter Michael Stadler , Mayer N. Fishman , Ulka N. Vaishampayan , Jacek K. Pinski , Sumanta K. Pal , James Hu , David I. Quinn , Primo Lara Jr.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT01727089
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 522)
DOI
10.1200/jco.2016.34.2_suppl.522
Abstract #
522
Poster Bd #
E5
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Bevacizumab (Bev) alone or in combination with TRC105 for metastatic renal cell cancer (mRCC): A California Cancer Consortium clinical trial.
First Author: Tanya B. Dorff
Poster
2017 ASCO Annual Meeting
Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF therapy.
First Author: Yingmiao Liu
Poster
2015 Genitourinary Cancers Symposium
A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma.
First Author: Toni K. Choueiri
Poster
2014 ASCO Annual Meeting
Biomarker modulation in patients (pts) receiving TRC105 (T) and bevacizumab (B) in a phase Ib clinical trial.
First Author: Yingmiao Liu